Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program
Broadened Tissue Tropism: The blend may extend regenerative action across muscle, tendon, nerve, and epithelial tissues, thereby enhancing functional recovery in diverse models of injury
Unlike full-length growth hormone, AOD-9604 is researched for its ability to stimulate fat breakdown and inhibit fat accumulation without significantly impacting IGF-1 levels or causing broad growth effects
T., Yi, E., Jin, X., Zheng, Q., Park, S., Yi, G., Yang, S., & Yi, T
US$ 20.40
US$ 20.61
US$ 25.33
US$ 25.89
US$ 25.81
